Literature DB >> 35934321

Analytical Validation and Performance Characteristics of Molecular Serum Biomarkers, miR-371a-3p and miR-372-3p, for Male Germ Cell Tumors, in a Clinical Laboratory Setting.

Fei Ye1, Darren R Feldman2, Alisa Valentino3, Rachel So3, Maria Bromberg4, Shah Khan4, Samuel A Funt2, Joel Sheinfeld5, David B Solit6, Melissa S Pessin3, Ellinor I Peerschke7.   

Abstract

Detection of serum embryonic miRNAs miR-371a-3p and miR-372-3p has been proposed to aid in diagnosis, prognosis, and management of patients with testicular germ cell tumors (GCTs). This study describes the analytical validation and performance of a laboratory-developed test to detect these miRNA targets by stem loop real-time quantitative RT-PCR (RT-qPCR) in serum from patients with GCTs. The assay was standardized using an exogenous spike-in control of nonhuman miRNA from Caenorhabditis elegans (cel-miR-39-3p) to assess extraction efficiency, and an endogenous housekeeping miRNA, miR-30b-5p, to control for miRNA normalization. miRNA results were expressed as relative expression level, using the comparative threshold cycle method (2ΔΔCT). Analytical sensitivity of miR-371a-3p and miR-372-3p was 12.5 and 1.25 copies/μL, respectively. Clinical accuracy was evaluated using GCT patients with (n = 34) and without (n = 17) active disease. Positive/negative cutoffs and indeterminate findings were established on the basis of results from healthy volunteers (n = 25) and assay precision. miR-371a-3p and miR-372-3p exhibited a sensitivity of 81.8% and 87.5%, respectively, and a specificity of 100% and 94%, respectively, and an area under the receiver operating characteristic curve of 0.93 and 0.95, respectively. Taken together, RT-qPCR testing for serum miR-371a-3p and miR-372-3p represents a robust, sensitive, and specific clinical assay to aid in the clinical management of patients with GCT.
Copyright © 2022 Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35934321      PMCID: PMC9379668          DOI: 10.1016/j.jmoldx.2022.04.007

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.341


  36 in total

1.  Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study.

Authors:  Hege S Haugnes; Torgeir Wethal; Nina Aass; Olav Dahl; Olbjørn Klepp; Carl W Langberg; Tom Wilsgaard; Roy M Bremnes; Sophie D Fosså
Journal:  J Clin Oncol       Date:  2010-09-20       Impact factor: 44.544

2.  Serum Levels of MicroRNA miR-371a-3p: A Sensitive and Specific New Biomarker for Germ Cell Tumours.

Authors:  Klaus-Peter Dieckmann; Arlo Radtke; Meike Spiekermann; Thomas Balks; Cord Matthies; Pascal Becker; Christian Ruf; Christoph Oing; Karin Oechsle; Carsten Bokemeyer; Johannes Hammel; Sebastian Melchior; Werner Wosniok; Gazanfer Belge
Journal:  Eur Urol       Date:  2016-08-02       Impact factor: 20.096

Review 3.  Testicular germ-cell tumours in a broader perspective.

Authors:  J Wolter Oosterhuis; Leendert H J Looijenga
Journal:  Nat Rev Cancer       Date:  2005-03       Impact factor: 60.716

Review 4.  Application of miRNAs in the diagnosis and monitoring of testicular germ cell tumours.

Authors:  Kristian Almstrup; João Lobo; Nina Mørup; Gazanfer Belge; Ewa Rajpert-De Meyts; Leendert H J Looijenga; Klaus-Peter Dieckmann
Journal:  Nat Rev Urol       Date:  2020-03-10       Impact factor: 14.432

Review 5.  The present and future of serum diagnostic tests for testicular germ cell tumours.

Authors:  Matthew J Murray; Robert A Huddart; Nicholas Coleman
Journal:  Nat Rev Urol       Date:  2016-10-18       Impact factor: 14.432

6.  Predictive biomarkers in bladder cancer.

Authors:  Marwan Alkassis; Hampig R Kourie; Julien Sarkis; Elie Nemr
Journal:  Biomark Med       Date:  2021-02-24       Impact factor: 2.851

7.  Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study.

Authors:  Klaus-Peter Dieckmann; Arlo Radtke; Lajos Geczi; Cord Matthies; Petra Anheuser; Ulrike Eckardt; Jörg Sommer; Friedemann Zengerling; Emanuela Trenti; Renate Pichler; Hanjo Belz; Stefan Zastrow; Alexander Winter; Sebastian Melchior; Johannes Hammel; Jennifer Kranz; Marius Bolten; Susanne Krege; Björn Haben; Wolfgang Loidl; Christian Guido Ruf; Julia Heinzelbecker; Axel Heidenreich; Jann Frederik Cremers; Christoph Oing; Thomas Hermanns; Christian Daniel Fankhauser; Silke Gillessen; Hermann Reichegger; Richard Cathomas; Martin Pichler; Marcus Hentrich; Klaus Eredics; Anja Lorch; Christian Wülfing; Sven Peine; Werner Wosniok; Carsten Bokemeyer; Gazanfer Belge
Journal:  J Clin Oncol       Date:  2019-03-15       Impact factor: 44.544

8.  A pipeline to quantify serum and cerebrospinal fluid microRNAs for diagnosis and detection of relapse in paediatric malignant germ-cell tumours.

Authors:  Matthew J Murray; Emma Bell; Katie L Raby; Martin A Rijlaarsdam; Ad J M Gillis; Leendert H J Looijenga; Helen Brown; Benoit Destenaves; James C Nicholson; Nicholas Coleman
Journal:  Br J Cancer       Date:  2015-12-15       Impact factor: 7.640

9.  Part 1: Simple Definition and Calculation of Accuracy, Sensitivity and Specificity.

Authors:  Alireza Baratloo; Mostafa Hosseini; Ahmed Negida; Gehad El Ashal
Journal:  Emerg (Tehran)       Date:  2015

10.  Circulating MicroRNAs, the Next-Generation Serum Biomarkers in Testicular Germ Cell Tumours: A Systematic Review.

Authors:  Ricardo Leão; Maarten Albersen; Leendert H J Looijenga; Torgrim Tandstad; Christian Kollmannsberger; Matthew J Murray; Stephane Culine; Nicholas Coleman; Gazanfer Belge; Robert J Hamilton; Klaus-Peter Dieckmann
Journal:  Eur Urol       Date:  2021-06-24       Impact factor: 20.096

View more
  1 in total

1.  The values of systemic immune-inflammation index and neutrophil-lymphocyte ratio in predicting testicular germ cell tumors: A retrospective clinical study.

Authors:  Shuo Wang; Xiao Yang; Ziyi Yu; Peng Du; Yudong Cao; Yongpeng Ji; Jinchao Ma; Yong Yang
Journal:  Front Oncol       Date:  2022-09-16       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.